News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SAGE Therapeutics Announces Pricing Of Initial Public Offering



7/18/2014 10:58:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, Inc., a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts. All of the common stock is being offered by SAGE. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from SAGE at the public offering price to cover over-allotments, if any. The company’s shares are expected to begin trading on the NASDAQ Global Market on Friday, July 18, 2014 under the ticker symbol “SAGE.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES